B
Ben O'Leary
Researcher at Institute of Cancer Research
Publications - 33
Citations - 2498
Ben O'Leary is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Palbociclib & Cancer. The author has an hindex of 13, co-authored 29 publications receiving 1736 citations. Previous affiliations of Ben O'Leary include University of Cambridge & Breast Cancer Now.
Papers
More filters
Journal ArticleDOI
Treating cancer with selective CDK4/6 inhibitors
TL;DR: Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile.
Journal ArticleDOI
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Charlotte Fribbens,Ben O'Leary,Lucy Kilburn,Sarah Hrebien,Isaac Garcia-Murillas,Matthew Beaney,Massimo Cristofanilli,Fabrice Andre,Sherene Loi,Sibylle Loibl,John Jiang,Cynthia Huang Bartlett,Maria Koehler,Mitch Dowsett,Judith M Bliss,Stephen R. D. Johnston,Nicholas C. Turner +16 more
TL;DR: ESR1 mutation analysis in plasma after progression after prior AI therapy may help direct choice of further endocrine-based therapy, and improve progression-free survival after taking fulvestrant.
Journal ArticleDOI
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary,Ben O'Leary,Rosalind J. Cutts,Yuan Liu,Sarah Hrebien,Xin Huang,Kerry Fenwick,Fabrice Andre,Sibylle Loibl,Sherene Loi,Isaac Garcia-Murillas,Massimo Cristofanilli,Cynthia Huang Bartlett,Nicholas C. Turner,Nicholas C. Turner +14 more
TL;DR: It is shown that clonal evolution occurs frequently during treatment, reflecting substantial subclonal complexity in breast cancer that has progressed after prior endocrine therapy and suggests that early and late progression have distinct mechanisms of resistance.
Journal ArticleDOI
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Ben O'Leary,Sarah Hrebien,James P Morden,Matthew Beaney,Charlotte Fribbens,Charlotte Fribbens,Xin Huang,Yuan Liu,Cynthia Huang Bartlett,Maria Koehler,Massimo Cristofanilli,Isaac Garcia-Murillas,Judith M Bliss,Nicholas C. Turner,Nicholas C. Turner +14 more
TL;DR: CTDNA levels in CDK4/6 inhibitor treatment in advanced breast cancer are investigated, finding ctDNA levels predict progression-free survival and anticipate clonal selection.
Journal ArticleDOI
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Charlotte Fribbens,Charlotte Fribbens,I. Garcia Murillas,Matthew Beaney,S. Hrebien,Ben O'Leary,Lucy Kilburn,K. Howarth,Michael Epstein,Emma Green,Nitzan Rosenfeld,Alistair Ring,S.R.D. Johnston,Nicholas C. Turner,Nicholas C. Turner +14 more
TL;DR: Cancers progressing on the first-line AI show high levels of genetic heterogeneity, with frequent sub-clonal mutations, and KRAS mutations are found at high frequency.